Table 2.
• Arm with radionuclide (e.g., 90Y or 131I) |
• Treat earlier! |
• Radiation dose intensification: “more and longer” |
• Larger doses, (e.g., SCT) |
• More doses (e.g., multiple doses or fractionation) |
• Better-defined patient population, using imaging |
• Small molecule radionuclide carriers |
• Pretargeted RIT |
• mAb alternatives (e.g., mAb fragments, affibodies, aptamers, SHALs, peptides, etc.) |
SCT, stem cell transplantation; RIT, radioimmunotherapy; mAb, monoclonal antibody; SHALs, selected high-affinity ligands.